CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Clinical trial NCT06179524 · RECRUITING

Trial details

NCT number: NCT06179524
Sponsor: Beijing Yongtai Ruike Biotechnology Company Ltd
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed B-cell Acute Lymphoblastic Leukemia Refractory B-cell Acute Lymphoblastic Leukemia

Start date: 2024-01-03
Primary completion: 2025-06-30
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.